Skip to content

Reported May 13, 2025 · Before market open

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.05

Financials

Q1 2025

Income statement

See full
Operating income-$6.1M+37.1%
Net income-$5.8M+39.2%
EPS (diluted)-$0.07+66.7%

Balance sheet

See full
Cash & equivalents$28.4M+54.2%
Total debt$870.0K+8.6%
Total equity$27.8M+187%
Total assets$35.0M+43.1%

Cash flow

See full
Operating cash flow-$9.1M+15.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$98.11M+76.2%
Enterprise value$70.59M+85.3%

Returns & leverage

See full
Return on equity-144.9%-50.7pp
Debt / equity-0.1×
Current ratio4.6×+3.2×

Versus estimates

Ask the moment SELLAS Life Sciences Group, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did SELLAS Life Sciences Group, Inc. report Q1 2025 earnings?
SELLAS Life Sciences Group, Inc. (SLS) reported Q1 2025 earnings on May 13, 2025 before market open.
What were SELLAS Life Sciences Group, Inc.'s Q1 2025 revenue and EPS?
SELLAS Life Sciences Group, Inc. reported diluted EPS of $-0.07 for Q1 2025.
Did SELLAS Life Sciences Group, Inc. beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.10 by $0.03.
How did SELLAS Life Sciences Group, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 66.7% from $-0.21.
Where can I find SELLAS Life Sciences Group, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0001390478-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.